{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:50:29Z","timestamp":1790383829902,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.diagmicrobio.2010.10.031","type":"journal-article","created":{"date-parts":[[2011,2,25]],"date-time":"2011-02-25T04:40:17Z","timestamp":1298608817000},"page":"342-347","source":"Crossref","is-referenced-by-count":32,"title":["In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007\u20132009 study"],"prefix":"10.1016","volume":"69","author":[{"given":"James A.","family":"Karlowsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Poutanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl J.","family":"Hoban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Zhanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0005","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1128\/AAC.01453-08","article-title":"Activities of dalbavancin against a worldwide collection of 81,673 Gram-positive bacterial isolates","volume":"53","author":"Biedenbach","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0010","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1128\/JCM.02368-06","article-title":"Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States","volume":"45","author":"Biedenbach","year":"2007","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1742-1241.2007.01318.x","article-title":"Dalbavancin: a novel antimicrobial","volume":"61","author":"Chen","year":"2007","journal-title":"Int. J. Clinic. Practice."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0020","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1128\/JCM.02500-06","article-title":"Comparative genomics of Canadian epidemic lineages of methicillin-resistant Staphylococcus aureus","volume":"45","author":"Christianson","year":"2007","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0025","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard-seventh edition, M7-A7","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2006"},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0030","series-title":"Performance standards for antimicrobial susceptibility testing: 20th information supplement (M100-S20)","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2010"},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2217\/17460913.3.3.251","article-title":"Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens","volume":"3","author":"Crandon","year":"2008","journal-title":"Future Microbiol."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0040","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1128\/AAC.01641-07","article-title":"Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States","volume":"52","author":"Draghi","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0045","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0163-4453(09)60004-9","article-title":"Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria","volume":"59","author":"Eliopoulos","year":"2009","journal-title":"J. Infect."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0050","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1128\/AAC.00620-06","article-title":"Bactericidal activity and resistance development profiling of dalbavancin","volume":"51","author":"Goldstein","year":"2007","journal-title":"Antimicrob. Agents Chemother.."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1469-0691.2004.01051.x","article-title":"Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres","volume":"11","author":"Gales","year":"2005","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0060","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2008\/754249","article-title":"A preliminary guideline for the assignment of methicillin-resistant Staphylococcus aureus to a Canadian pulsed-field electrophoresis epidemic type using spa typing","volume":"19","author":"Golding","year":"2008","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0065","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.diagmicrobio.2010.10.024","article-title":"Introduction to the CANWARD study, 2007\u20132009","volume":"69","author":"Hoban","year":"2011","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.diagmicrobio.2005.08.015","article-title":"Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004)","volume":"54","author":"Jones","year":"2006","journal-title":"Diagn. Microb. Infect. Dis."},{"issue":"58","key":"10.1016\/j.diagmicrobio.2010.10.031_bb0075","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/jac\/dkl235","article-title":"Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus","volume":"2006","author":"Leuthner","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0080","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.00301-10","article-title":"In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates","volume":"54","author":"Mendes","year":"2010","journal-title":"Antimicrob. Agents Chemother.."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0085","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1128\/JCM.39.10.3481-3485.2001","article-title":"Development of a Canadian standardized protocol for subtyping methicillin-resistant Staphylococcus aureus using pulsed-field gel electrophoresis","volume":"39","author":"Mulvey","year":"2001","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0090","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3201\/eid1106.041146","article-title":"Community-associated methicillin-resistant Staphylococcus aureus","volume":"11","author":"Mulvey","year":"2005","journal-title":"Canada. Emerg. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0095","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1128\/AAC.46.7.2155-2161.2002","article-title":"Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus","volume":"46","author":"Oliveira","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0100","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1086\/648438","article-title":"Telavancin: a novel lipoglycopeptide","volume":"49","author":"Saravolatz","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0105","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.diagmicrobio.2005.03.004","article-title":"Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens","volume":"53","author":"Streit","year":"2005","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0115","series-title":"Vibativ (telavancin) for injection, package insert","author":"Vibativ","year":"2009"},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0120","first-page":"25","article-title":"Activity of dalbavancin against S. aureus, S. epidermidis, S. pneumoniae, and Enterococcus spp. isolated from Canadian hospitals: CANWARD 2007. Presented at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C.","volume":"2008","author":"Weshnoweski","year":"2008","journal-title":"October"},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0125","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.diagmicrobio.2010.10.025","article-title":"Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007\u20132009 study","volume":"69","author":"Zhanel","year":"2011","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.diagmicrobio.2008.04.012","article-title":"Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005\/2006","volume":"62","author":"Zhanel","year":"2008","journal-title":"Diagn. Microb. Infect. Dis."},{"key":"10.1016\/j.diagmicrobio.2010.10.031_bb0135","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889310005018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889310005018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T17:18:53Z","timestamp":1560014333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889310005018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0732889310005018"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2010.10.031","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}